Table 1.
Characteristics of included studies.
| Study | Vaccine | Participants (Young/Old) |
Controls (Young/Old) |
Age Range (Young/Old) |
Country |
|---|---|---|---|---|---|
| J. Sadoff et al. | Ad26.COV2.S | 162/161 | 82/81 | 18–55/≥65 | Belgium and United States |
| Shengli Xia et al. | BBIBP-CorV | 72/72 | 24/24 | 18–59/≥60 | China |
| Jingxin Li et al. | BNT162b1 | 48/48 | 24/24 | 18–55/65–85 | China |
| Maheshi N Ramasamy et al. | ChAdOx1 | 50/96 | 49/20 | 18–55/≥70 | United Kingdom |
| Gang Zeng et al. | CoronaVac | 430/256 | 110/47 | 18–59/≥60 | China |
| Jiankai Liu et al. | KCONVAC | 200/200 | 50/50 | 18–59/≥60 | China |
| Neil Formica et al. | NVX-CoV2373 | 561/467 | 139/116 | 18–59/≥60 | United States, Australia |
| Ya-Jun Shu et al. | V-01 | 360/360 | 80/80 | 18–59/≥60 | China |